Table 3 Risk factors for overall mortality in patients with and without hepatocellular carcinoma.
Univariable | Multivariable | |||
|---|---|---|---|---|
HR (95% CI) | P | HR (95% CI) | P | |
Patients with HCC | ||||
Elderly recipient (age ≥ 60 years) | 0.689 (0.382–1.242) | 0.215 | ||
Female sex | 0.598 (0.286–1.251) | 0.172 | 0.545 (0.259–1.145) | 0.109 |
High tacrolimus IPV (CV > 30%) | 2.600 (1.602–4.221) | < 0.001 | 3.010 (1.842–4.918) | < 0.001 |
Mean tacrolimus level, ng/mL | 1.045 (0.919–1.188) | 0.500 | ||
Donor age, per year | 1.022 (1.004–1.040) | 0.014 | 1.024 (1.006–1.043) | 0.009 |
Donor female sex | 1.192 (0.731–1.942) | 0.482 | ||
Deceased donor | 1.815 (1.113–2.959) | 0.017 | ||
MELD Na score > 25 | 1.503 (0.745–3.035) | 0.255 | ||
AFP > 100 IU/mL | 4.296 (2.515–7.336) | < 0.001 | 4.833 (2.811–8.309) | < 0.001 |
mTOR inhibitor | 0.732 (0.394–1.358) | 0.323 | ||
Patients without HCC | ||||
Elderly recipient (age ≥ 60 years) | 3.157 (1.516–6.575) | 0.002 | 2.493 (1.191–5.218) | 0.015 |
Female sex | 1.303 (0.658–2.580) | 0.448 | ||
High tacrolimus IPV (CV > 30%) | 1.480 (0.730–2.999) | 0.277 | ||
Mean tacrolimus level, ng/mL | 1.020 (0.840–1.239) | 0.842 | ||
Donor age, per year | 1.040 (1.014–1.067) | 0.002 | 1.039 (1.012–1.066) | 0.004 |
Donor female sex | 1.076 (0.539–2.149) | 0.836 | ||
Deceased donor | 2.022 (1.020–4.009) | 0.044 | ||
MELD Na score > 25 | 0.685 (0.334–1.406) | 0.302 | ||
HBV-related liver disease | 0.281 (0.121–0.650) | 0.003 | 0.342 (0.146–0.801) | 0.014 |
